Uveal Melanoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Uveal melanoma symptoms include dark spot on the iris, glaucoma, eye pain, and eye redness. Treatment for the disease includes surgery, radiation, and proton therapy.
The Uveal Melanoma pipeline drugs market research report provides an overview of the Uveal Melanoma (Oncology) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Uveal Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Uveal Melanoma (Oncology) and features dormant and discontinued projects.
Uveal Melanoma Pipeline Drugs Market by Key Targets
Some of the key targets of the Uveal Melanoma pipeline drugs market are Cytotoxic T Lymphocyte Protein 4, Programmed Cell Death Protein 1, Focal Adhesion Kinase, Protein Kinase C, ALK Tyrosine Kinase Receptor, BDNF/NT 3 Growth Factors Receptor, Cells Expressing Melanoma Antigen Preferentially Expressed In Tumors, Dual Specificity Mitogen Activated Protein Kinase Kinase 1, Hepatocyte Growth Factor Receptor, and Mast/Stem Cell Growth Factor Receptor Kit.
Uveal Melanoma Pipeline Drugs Market, by Targets
For more target insights, download a free report sample
Key Mechanism of Actions in the Uveal Melanoma Pipeline Drugs Market
Some of the key mechanism of actions of the Uveal Melanoma pipeline drugs market are Programmed Cell Death Protein 1 Antagonist, Cytotoxic T Lymphocyte Protein 4 Antagonist, Focal Adhesion Kinase Inhibitor, Protein Kinase C Inhibitor, ALK Tyrosine Kinase Receptor Inhibitor, BDNF/NT 3 Growth Factors Receptor Inhibitor, Cytotoxic T Lymphocyte Protein 4 Inhibitor, Cytotoxic To Cells Expressing Melanoma Antigen Preferentially Expressed In Tumors, Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Inhibitor, and Mast/Stem Cell Growth Factor Receptor Kit Inhibitor.
Uveal Melanoma Pipeline Drugs Market, by Mechanism of Actions
For more mechanism of action insights, download a free report sample
Key Routes of Administration in the Uveal Melanoma Pipeline Drugs Market
The key routes of administration in the Uveal Melanoma pipeline drugs market are intravenous, oral, subcutaneous, intratumor, parenteral, intralesional, intraperitoneal, intravitreal, intradermal, and intramuscular.
Uveal Melanoma Pipeline Drugs Market, by Routes of Administration
For more routes of administration insights, download a free report sample
Key Molecule Types in the Uveal Melanoma Pipeline Drugs Market
The key molecule types in the Uveal Melanoma pipeline drugs market are small molecule, monoclonal antibody, cell therapy, fusion protein, recombinant protein, monoclonal antibody conjugated, oncolytic virus, antisense oligonucleotide, gene-modified cell therapy, and gene therapy.
Uveal Melanoma Pipeline Drugs Market, by Molecule Types
For more molecule type insights, download a free report sample
Key Companies in the Uveal Melanoma Pipeline Drugs Market
Some of the key companies in the Uveal Melanoma pipeline drugs market are Bristol-Myers Squibb Co, Lyvgen Biopharma Ltd, Pfizer Inc, Aura Biosciences Inc, Ideaya Biosciences Inc, InxMed (Beijing) Co Ltd, Modulation Therapeutics Inc, Novartis AG, OncoSpherix Inc, and Oxular Ltd.
Uveal Melanoma Pipeline Drugs Market, by Companies
To know more about the companies, download a free report sample
Uveal Melanoma Pipeline Drugs Market Report Overview
| Key Targets | Cytotoxic T Lymphocyte Protein 4, Programmed Cell Death Protein 1, Focal Adhesion Kinase, Protein Kinase C, ALK Tyrosine Kinase Receptor, BDNF/NT 3 Growth Factors Receptor, Cells Expressing Melanoma Antigen Preferentially Expressed In Tumors, Dual Specificity Mitogen Activated Protein Kinase Kinase 1, Hepatocyte Growth Factor Receptor, and Mast/Stem Cell Growth Factor Receptor Kit |
| Key Mechanism of Actions | Programmed Cell Death Protein 1 Antagonist, Cytotoxic T Lymphocyte Protein 4 Antagonist, Focal Adhesion Kinase Inhibitor, Protein Kinase C Inhibitor, ALK Tyrosine Kinase Receptor Inhibitor, BDNF/NT 3 Growth Factors Receptor Inhibitor, Cytotoxic T Lymphocyte Protein 4 Inhibitor, Cytotoxic To Cells Expressing Melanoma Antigen Preferentially Expressed In Tumors, Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Inhibitor, and Mast/Stem Cell Growth Factor Receptor Kit Inhibitor |
| Key Routes of Administration | Intravenous, Oral, Subcutaneous, Intratumor, Parenteral, Intralesional, Intraperitoneal, Intravitreal, Intradermal, and Intramuscular |
| Key Molecule Types | Small Molecule, Monoclonal Antibody, Cell Therapy, Fusion Protein, Recombinant Protein, Monoclonal Antibody Conjugated, Oncolytic Virus, Antisense Oligonucleotide, Gene-Modified Cell Therapy, and Gene Therapy |
| Key Companies | Bristol-Myers Squibb Co, Lyvgen Biopharma Ltd, Pfizer Inc, Aura Biosciences Inc, Ideaya Biosciences Inc, InxMed (Beijing) Co Ltd, Modulation Therapeutics Inc, Novartis AG, OncoSpherix Inc, and Oxular Ltd |
Scope
This report provides:
- A snapshot of the global therapeutic landscape of Uveal Melanoma (Oncology).
- Reviews of pipeline therapeutics for Uveal Melanoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- Reviews of key companies involved in Uveal Melanoma (Oncology) therapeutics and enlists all their major and minor projects.
- Evaluation of Uveal Melanoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news related to pipeline therapeutics for Uveal Melanoma (Oncology).
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Uveal Melanoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Uveal Melanoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Acrotech Biopharma LLC
Adagene Suzhou Ltd
Aeglea BioTherapeutics Inc
Alpine Immune Sciences Inc
Astellas Pharma Inc
Astex Pharmaceuticals Inc
Aura Biosciences Inc
Bellicum Pharmaceuticals Inc
Biogazelle NV
BioMed Valley Discoveries Inc
Bristol-Myers Squibb Co
Byondis BV
Codiak BioSciences Inc
Delcath Systems Inc
Dompe Farmaceutici SpA
Exelixis Inc
F. Hoffmann-La Roche Ltd
Faron Pharmaceuticals Oy
Foghorn Therapeutics Inc
Fusion Pharmaceuticals Inc
GSK plc
Hillstream BioPharma Inc
Ideaya Biosciences Inc
Immunocore Holdings Plc
Immunocore Limited
Inventiva SA
InxMed (Beijing) Co Ltd
iOnctura SA
Kezar Life Sciences Inc
Kymera Therapeutics Inc
Kyorin Pharmaceutical Co Ltd
Linnaeus Therapeutics Inc
Lyvgen Biopharma Ltd
Merck & Co Inc
Mereo Biopharma Group Plc
Modulation Therapeutics Inc
Novartis AG
Okogen Inc
Oncomatryx Biopharma SL
OncoSpherix Inc
Ono Pharmaceutical Co Ltd
Oxular Ltd
Pfizer Inc
Plexxikon Inc
Prelude Therapeutics Inc
Provectus Biopharmaceuticals Inc
Regeneron Pharmaceuticals Inc
Replimune Ltd
Rubius Therapeutics Inc
Sapience Therapeutics Inc
Seagen Inc
Statera Biopharma Inc
TriSalus Life Sciences Inc
Vanquish Oncology Inc
Verastem Inc
WPD Pharmaceuticals Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets of the Uveal Melanoma pipeline drugs market?
Some of the key targets of the Uveal Melanoma pipeline drugs market are Cytotoxic T Lymphocyte Protein 4, Programmed Cell Death Protein 1, Focal Adhesion Kinase, Protein Kinase C, ALK Tyrosine Kinase Receptor, BDNF/NT 3 Growth Factors Receptor, Cells Expressing Melanoma Antigen Preferentially Expressed In Tumors, Dual Specificity Mitogen Activated Protein Kinase Kinase 1, Hepatocyte Growth Factor Receptor, and Mast/Stem Cell Growth Factor Receptor Kit.
-
What are the key mechanism of actions of the Uveal Melanoma pipeline drugs market?
Some of the key mechanism of actions of the Uveal Melanoma pipeline drugs market are Programmed Cell Death Protein 1 Antagonist, Cytotoxic T Lymphocyte Protein 4 Antagonist, Focal Adhesion Kinase Inhibitor, Protein Kinase C Inhibitor, ALK Tyrosine Kinase Receptor Inhibitor, BDNF/NT 3 Growth Factors Receptor Inhibitor, Cytotoxic T Lymphocyte Protein 4 Inhibitor, Cytotoxic To Cells Expressing Melanoma Antigen Preferentially Expressed In Tumors, Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Inhibitor, and Mast/Stem Cell Growth Factor Receptor Kit Inhibitor.
-
What are the key routes of administration in the Uveal Melanoma pipeline drugs market?
The key routes of administration in the Uveal Melanoma pipeline drugs market are intravenous, oral, subcutaneous, intratumor, parenteral, intralesional, intraperitoneal, intravitreal, intradermal, and intramuscular.
-
What are the key molecule types in the Uveal Melanoma pipeline drugs market?
The key molecule types in the Uveal Melanoma pipeline drugs market small molecule, monoclonal antibody, cell therapy, fusion protein, recombinant protein, monoclonal antibody conjugated, oncolytic virus, antisense oligonucleotide, gene-modified cell therapy, and gene therapy.
-
Which are the key companies in the Uveal Melanoma pipeline drugs market?
Some of the key companies in the Uveal Melanoma pipeline drugs market are Bristol-Myers Squibb Co, Lyvgen Biopharma Ltd, Pfizer Inc, Aura Biosciences Inc, Ideaya Biosciences Inc, InxMed (Beijing) Co Ltd, Modulation Therapeutics Inc, Novartis AG, OncoSpherix Inc, and Oxular Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Oncology reports